Excellent feedback Southoz. BUT you need to understand the...

Excellent feedback Southoz.

BUT you need to understand the Professors thinking and approach to compiling and reporting data. Its detailed and in preparatiom, for submission at a major conference.This explains why it possibly took an extra 2 months to put the data and analysis together (initially due mid - June 16)

Look, when it comes the science..MSB have continuously presented excellent safety and efficacy in pre-clinical ( should not be understated) and in P2 trials in 15.5 years ( marketing/ communication/ managing retail shareholders is another story).
Of course its the P3 trials they will make the company.

This why MSB historically have always had medical KOL in the relevant application comment on there results.
Allan Gibofsky M.D., J.D. is a good example.
http://tregdocs.com/index.html?p=262.html

Like all professionals in there fields , you will not your name to a new concept or view ...if its slippery or scandalous ( just for a few bucks) . BUT where something is cutting edge - every leader in the relevant field wants part of it. Go back and listen to the Webcast and Allan Gibofsky M.D explains as much and WHY he decided to get involved with MSB.


Alpha have previously canned MSB efficacy results and in time they have are proven absolutely and undeniably incorrect ( like the best science ward in DDD recently and also DMC green light re ongoing CHF trials). They will be proven wrong again when MSB files BLA for Paediatric aGVHD in good time.

R.A is a massive field and 24 wks results (or 6 mths which will be on or around 30th Sept 16 ) will be presented in due course at a major Rheumatology conference ( mid Nov 2016).

One thing I do give Alpha ...they have developed a huge propensity to talk sheet!

GLTAH